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Abstract: The diagnosis of movement disorders including Parkinsonian syndromes and essential 
tremor is mainly clinical. The most common diagnostic errors for Parkinson’s disease include 
misdiagnoses such as Parkinson plus syndromes and cases of essential tremor. In this article, 
we discuss the clinical utility of DaTscan™ (123I-Ioflupane injection) and its diagnostic value 
in Parkinson’s disease and the other Parkinsonian syndromes. Single photon emission computed 
tomography with 123I-Ioflupane can be useful to assist in the diagnosis of uncertain cases of 
Parkinsonism. An accurate diagnosis can aid clinicians in making correct decisions that are 
related to the overall management and treatment of Parkinson’s disease, avoiding common 
therapeutic errors.
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An introduction to diagnostic issues 
in Parkinson’s disease
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder 
characterized by motor and nonmotor symptoms.1 PD is the second most common 
neurodegenerative disorder after dementia2 affecting approximately 1%–2% of the 
general population.3 The cardinal pathological feature of PD is the depletion of 
dopamine in the substantia nigra pars compacta.4
The diagnosis of PD is essentially clinical and is based on identifying clinical 
characteristics related to striatal dopamine depletion, which typically manifest as motor 
signs and symptoms (tremor, bradykinesia, and rigidity).5 In fact, a good response to 
dopaminergic medication is consistent with a typical case of idiopathic PD. However, 
a typical clinical image may not be fully manifested in early PD; nonmotor symptoms, 
such as sleep disorders and hyposmia may precede motor symptoms6 while depression, 
dementia, and fatigue can dominate over motor symptoms. In addition, comorbidity 
with neuropsychiatric conditions can act as confounding factors in the diagnostic 
process.
PD diagnosis is usually straightforward; however, common diagnostic errors can 
hamper the clinical management of true idiopathic PD cases. The most common 
diagnostic errors include misdiagnosed cases as dystonic or essential tremor (ET), 
progressive supranuclear palsy (PSP), multiple systemic atrophy (MSA), dementia 
with Lewy bodies (DLB), drug induced Parkinsonism, small vessel disease, and 
psychogenic disorders.
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An overview of current diagnostic 
strategies for movement disorders, 
such as clinical examinations, blood 
tests, and neuropsychological 
evaluations
PD diagnosis is based on information gathered from medical 
history and detailed neurological examination that focuses on 
the motor symptoms of the disorder. The United Kingdom 
PD brain bank criteria7 are widely used in clinical practice 
with an estimated specificity of 98.6% and a sensitivity of 
91.1% in diagnosing idiopathic PD (Table 1).8
Nonmotor symptoms of PD are assessed through several 
questionnaires that can be also used to record PD progression 
and severity. Depression is amongst the most common nonmotor 
features in PD affecting approximately 35% of patients.9 The 
clinical criteria for depression, as described in the Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition, text 
revision (DSM-IV-TR), the first part of the unified PD rating 
scale (UPDRS-I),10 or the Hamilton depression rating scale 
(HAM-D17)11 can be used to evaluate depressive disorder in 
early PD. To the best of our knowledge, the Parkinson’s fatigue 
scale (PFS-16) is the first rating scale of fatigue based on 
information acquired from the patients’ perspective.12
The time of dementia onset in PD varies. Cognitive 
impairment tends to be diagnosed within the first 3–5 years 
after the diagnosis of PD.13 The mini mental status examination 
(MMSE)14 and the Montreal cognitive assessment (MoCA)15 
questionnaires can nevertheless be used to evaluate cognitive 
decline in PD. Specifically, MoCA has been suggested to 
provide higher sensitivity for mild cognitive impairment in 
early PD than MMSE, while the latter seems to better follow 
up the progression of cognition problems.16 Still, both rating 
scales have not been assessed for their ability to differentiate 
the diagnosis of dementia in PD from DLB.
Olfactory function is impaired in approximately 90% of 
PD patients notably at a pre-symptomatic phase around 2–7 
years prior to the time that typical motor symptoms appear.17,18 
Testing of odor discriminating ability with the 40-item Uni-
versity of Pennsylvania identification smell test (UPSIT-40)19 
and the 16-item identification smell test20 could have potential 
differential diagnostic value. However, positive results from 
olfactory testing are apparently not robust enough to sug-
gest idiopathic PD. In addition, olfactory irregularity is not 
exclusive for PD; it has been also described in patients with 
PSP, MSA, ET, and Alzheimer’s disease (AD).21
Parasomnias and sleep disorders are amongst the most 
frequent nonmotor symptoms in PD and can mostly occur 
as disrupted sleep, sleep behavior disorders (rapid eye 
movement behavior disorder), sleep apnea, or insomnia.22 
The PD sleep scale23 and the Pittsburgh sleep quality index24 
can be used to monitor the stature of sleep, possible sleep 
problems, and their impact on the quality of life.
Several genomic loci have been related with sporadic PD 
cases,25 namely, as familial parkinsonian syndromes (familiar 
PSs) which are directly related to gene mutations. These have 
been reported to less than 10% of cases diagnosed with PD; 
of which, PARK8 (Leucine–rich repeat kinase 2, LRRK2, 
dardarin) and PARK1/PARK4 (α–synuclein, SNCA) have 
been found to cause autosomal dominant parkinsonism27–29 
whilst, PARK2 (Parkinson protein 2, E3 ubiquitin protein 
ligase, PARKIN), PARK6 [phosphatase and tensin homolog 
(PTEN)–induced putative kinase 1, PINK1] and PARK7 
(Parkinson protein 7, protein DJ1, DJ–1) have been identified 
as responsible for causing autosomal recessive disease.30–32 
However, sufficient knowledge in order to generate a 
genomic classification for the vast majority of PD patients 
and thus determine particular genetic profiles that could 
impact clinical practice is lacking. Serologic genetic tests 
are therefore rarely used in routine care for diagnostic 
purposes unless there is strong evidence of a familiar genetic 
background where counseling is indicated. Overall, there is 
no study to our knowledge that focuses on PD diagnosis and 
compares the strength of these tests against single photon 
emission computed tomography (SPECT) with 123Iodine-
ioflupane.
Review of chemistry, formulation,  
and mechanism of action of 
123I-Ioflupane injection (DaTscan™)
Neuroimaging techniques, such as magnetic resonance 
imaging (MRI), transcranial sonography, positron emission 
tomography (PET), and SPECT can be employed to detect 
structural and functional changes in vivo and therefore 
support a PD diagnosis. Specifically, PET and SPECT 
techniques can be utilized to sensitively detect dopamine 
terminal loss in unspecified clinical cases of Parkinsonism.
Table 1 UK Parkinson’s Disease Society Brain Bank clinical 
diagnostic criteria: Diagnosis of Parkinsonian syndrome
Bradykinesia (slowness of initiation or voluntary movement with 
progressive reduction in speed and amplitude of repetitive actions), and 
at least one of the following:
Muscular rigidity;
4–6 Hz rest tremor;
postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction.
Notes: Reproduced with permission of BMJ Publishing Group Ltd. Original Source: 
Hughes AJ, Daniel Se, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic 
Parkinson’s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg 
Psychiatry. 1992;55(3):181–184.7
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N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-[123I] 
iodophenyl) nortropane (123I-Ioflupane or 123I-β-FP-CIT; 
DaTscan™, GE Healthcare Ltd, Little Chalfont, UK) is 
a radio-iodinated cocaine analogue and is synthesized by 
the trialkyltin nonradioactive precursor SnFP-CT which is 
prepared from nor-β-CIT.33 An enhanced synthesis has also 
been proposed, which utilizes N-monofluroalkyl tropanes and 
fluoroalkyl iodides or fluoroalkyl sulfonate esters. Briefly, the 
synthetic process includes 123I labeling of the prepared tropane 
intermediate FP-CIT. The effective dose of this compound 
for adults and elderly in the striatum34 is 185 MBq/4.35 mSv 
(per 70 kg individual; Table 2; Figure 1).
123I-Ioflupane is a SPECT radioligand with high in vivo 
affinity for dopamine transporter (DAT).36 DAT is a sodium 
chloride dependent protein in dopaminergic terminals and is 
responsible for the reuptake of dopamine from the synaptic 
cleft back to the presynaptic neurons.37 Following the 
intravenous injection of 123I-Ioflupane, radioactive decay 
of 123I emits γ radiation. This can be detected externally 
through a γ camera which records the iodine radioactivity of 
several DAT-rich subregions of the brain. The main metabolic 
product of 123I-Ioflupane is FP-CIT acid, a polar compound 
that is unable to cross the blood-brain barrier. The other 
metabolites include nor-β-CIT and free iodine. Forty eight 
hours postinjection, about 60% of the injected radioactivity 
is excreted in the urine; fecal excretion is estimated to be at 
approximately 14%.38
I-Ioflupane (β-FP-CIT) labelled39,40 with 11C or 125I 
rapidly reaches high concentrations in the human striatum 
as suggested by autoradiography postmortem in vitro 
studies in humans, which was also confirmed by striatal 
accumulation of 11C-β-FP-CIT through PET in vivo imaging 
in a Cynomolgus monkey.39
However, 123I-Ioflupane has also been suggested to bind to 
the serotonin transporter (SERT) in humans.41 This theory was 
generated following a study in rats that noted high 123I-Ioflupane 
uptake in the hypothalamus.42 In the same study, acute challenge 
with vanoxerine (also known as GBR 12,909) administration 
(which blocks DAT), led to significant reductions in the striatal 
uptake of 123I-Ioflupane while fluvoxamine (a selective 
serotonin reuptake inhibitor) did not significantly affect the 
striatal uptake. On the other hand, fluvoxamine did reduce 
the uptake of the tracer in the serotonin-rich hypothalamus.42
Effectiveness of 123I-Ioflupane 
in differential diagnosis
123I-Ioflupane has been granted a marketing authorisation 
by The European Medicines Agency34 valid throughout the 
European Union in July 2000 (renewed in July 2010) and by 
the US Food and Drug Administration43 for the United States 
in January 2011. 123I-Ioflupane is indicated for assessing 
the loss of functional dopaminergic neuron terminals in 
the striatum in patients with clinically uncertain PSs which 
include PSP, MSA, DLB, drug-induced Parkinsonism, and 
small vessel diseases other than idiopathic PD.
In clinical practice, SPECT with 123I-Ioflupane can 
be reported as normal or abnormal through subjective 
visual rating of the 123I-Ioflupane signal. In other words, 
the examiner must observe SPECT images and judge to 
what extent the tracer is accumulated in the striatum based 
on background signal, which is assumed to be devoid of 
dopaminergic neurons. As a result, DAT imaging evaluation 
can vary greatly since the individual examiner’s opinion is 
based on their expertise and knowledge.44 Reduced DAT 
striatal binding is therefore suggested to depict reduced DAT 
availability which reflects striatal dopaminergic deficit.
123I-Ioflupane is indicated to discriminate between PSs 
and ET. In addition, it is indicated to assist in the differential 
diagnosis between probable DLB and AD. Hence, whereas 
the main diagnostic question refers to the integrity of the 
dopaminergic circuit in the striatum, DAT imaging can be 
utilized to investigate this and differentiate PD, PSP, MSA, or 
DLB from ET, secondary Parkinsonism, AD, and Huntington’s 
disease, in which the pathology is not related to dopaminergic 
depletion in the striatum.45 DAT imaging can therefore 
Table 2 Summarized characteristics of 123I-Ioflupane35
IUPAC name N-(3-Fluoropropyl)-2β-carbomethoxy-3β-
(4-[123I]iodophenyl)nortropane
Abbreviation [123I]FP-CIT, [123I]β-CIT-FP
Synonyms 123I-Ioflupane, DaTscan™
Target DAT [IC50 = 3.5 nM] 
Serotonin Transporter [IC50 = 9.73 nM]
Note: Adapted with permission of Molecular Imaging and Contrast Agent Database 
(MICAD). Leung K. N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-[123I]iodophenyl) 
nortropane. Bethesda: National Center for Biotechnology Information; 2004–2013. 
Available from: http://www.ncbi.nlm.nih.gov/books/NBK22986/.35 DaTscan™, Ge 
Healthcare Ltd, Little Chalfont, UK. 
Abbreviations: DAT, dopamine transporter; IC50, half maximal inhibitory 
concentration; IUPAC, International Union of Pure and Applied Chemistry.
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Figure 1 Chemical structure of 123I-Ioflupane.
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be particularly useful in the early stages of cases where 
bradykinesia and rigidity do not manifest as motor symptoms.
In such cases where the tremor is the dominant motor 
symptom, the diagnosis of either PD or ET is often based on 
clinical facts without performing DAT imaging. In some of 
these cases, a misdiagnosed case of ET can actually develop 
PD. It has been shown that patients with known ET have 
an approximately four times higher risk in developing PD 
than controls.46 In such cases, future imaging studies with 
123I-Ioflupane could possibly investigate the prognostic 
value of DAT imaging.
DP008–00347 and PDT–30448 studies were open 
randomized trials for assessing the efficacy of 123I-Ioflupane 
for DAT binding. The DP008-003 study was designed 
to estimate the accuracy of 123I-Ioflupane SPECT in 
confirming known clinical cases of PD against ET and healthy 
volunteers. PDT-304 was based on the diagnostic value of 
DAT imaging; in this study, the confirmation was clinical 
and came afterwards. Both studies were criticized by de la 
Fuente-Fernández in 2012.49 The accuracy of 123I-Ioflupane 
was calculated with a sensitivity of 98% and a specificity of 
67% for a possible and probable PD diagnosis in true early 
PD cases. In already established PD diagnoses, the specificity 
raises to 94%. However, this ability has not been questioned 
against neuropathological confirmation. Overall, future 
comparative studies can clarify this point and increase the 
accuracy of 123I-Ioflupane in differential diagnoses.
Among PD, PSP, and MSA, the uptake of 123I-Ioflupane 
has been found to be significantly more reduced in PSP 
patients than in PD or MSA cases; specifically when using 
putamen as a region of interest.50 Of interest, putamen/
caudate ratios were calculated in the same study50 and it 
was suggested that PSP patients follow a different pattern 
of dopaminergic degeneration compared to idiopathic PD. 
Another study51 suggests that patients with PSs and not 
PD, eventually show a decrease in dopamine D2 receptors, 
availability. However, this stemmed from comparisons of 
imaging data between 123I-Ioflupane and 123I-iodobenzamide 
(IBZM), which is a radiotracer specific to postsynaptic 
dopamine D2 receptors. An 123I-IBZM SPECT can be 
therefore useful only for supporting abnormal imaging with 
123I-Ioflupane.
SPECT with 123I-Ioflupane has been employed in a 
group of patients with corticobasal ganglionic degeneration 
and showed variable nigrostriatal reductions of the tracer 
characterized by greater hemispheric asymmetry compared 
to PD. Despite prominent bilateral disease, about 10% of cor-
ticobasal ganglionic degeneration patients of the same series 
had normal DAT imaging, which may suggest supranigral 
pathology for corticobasal ganglionic degeneration.52
SPECT with 123I-Ioflupane focused on striatal DAT 
availability is able to differentiate PD from ET with a 
sensitivity of 95% and a specificity of 93%.47 Also, idiopathic 
PD can be differentiated from secondary PD through SPECT 
with 123I-Ioflupane. However, the diagnostic accuracy of 
123I-Ioflupane is suggested to be low between idiopathic PD 
and atypical PSs.53 Parkinsonism due to vascular background 
is sometimes hard to distinguish from true idiopathic PD 
cases; vascular lesions are often found incidentally in elderly 
patients in MRI scans. However, a rather symmetrical uptake 
of striatal 123I-Ioflupane has been suggested to relate to 
vascular Parkinsonism.54,55 Thus, new prospective studies are 
needed to determine the prognostic value of 123I-Ioflupane 
for the diagnosis of vascular Parkinsonism.
123I-Ioflupane SPECT for DLB patients has been 
found to correlate with neuropathological validation of the 
disorder. Following postmortem analysis in eight patients 
with DLB compared to nine with AD, SPECT imaging with 
123I-Ioflupane almost 10 years before autopsy, was found 
to have a sensitivity and specificity of 88% and 100% for 
DLB diagnosis.56
123I-Ioflupane can be also employed to differentiate PD 
from psychogenic Parkinsonism, where nigrostriatal innervation 
should remain intact. 123I-Ioflupane SPECT data have 
suggested undamaged dopaminergic nigrostriatal terminals 
in case studies with psychogenic Parkinsonsism.57,58
Advantages and disadvantages 
of 123I-Ioflupane
123I-Ioflupane is used in routine clinical practice through 
subjective visual rating, a fact that weakens its robustness. 
However, objectivity may come through a region of interest 
approach or voxel-based techniques that can enhance its 
wide clinical use.44
From a methodology point of view, images of SPECT with 
123I-Ioflupane can be quantified through several methods 
such as a region of interest (ROI), one-shape analysis of 
the uptake, Statistical Parametric Mapping (SPM) analysis 
based on ROI/background ratios, and principal component 
analysis.59 Others are based on the machine learning paradigm 
that can be applied to the SPECT images through computer-
aided diagnosis systems that can assist the diagnosis of PSs.60 
An interesting method for quantitative measure of uptake has 
been proposed to assist the diagnosis of uncertain PSs and 
possibly measure disease progression59. This method combines 
principal components analysis and provides an automatic 
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classification as PS or nonPS with an accuracy measured at 
approximately 94.8%. Further to this work, another group 
proposed an improved automatic computer-aided diagnosis 
system with similar results (accuracy of approximately 
94%).61 Hence, image quantification can provide objectivity 
in order to avoid incorrect qualification for bilateral symmetric 
reduction sometimes found in MSA or PSP.
123I-Ioflupane has been proven to increase the diagnostic 
confidence for uncertain Parkinsonian cases when they 
clinically resemble idiopathic PD. When the clinical 
evaluation is not clear and there is a need for assessing in vivo 
the striatal dopaminergic deficit in movement disorders, 
SPECT with 123I-Ioflupane is indicated to support the 
clinical diagnosis. Less diagnostic errors enhance good 
clinical practice and reduce further costs and inappropriate 
anti-Parkinsonian treatment.
A recent study collected 1701 123I-FP-CIT SPECT scans 
of patients with uncertain clinical PSs. A cost-effectiveness 
analysis model was applied in this registry and it was shown 
that DAT imaging is influential in the diagnosis and further 
pharmacological management of patients with uncertain 
PSs.62 To this point, another study has proposed potential 
cost savings in treatment of PD.63 However, future cost-
effectiveness studies should focus on the prognostic value of 
SPECT imaging with 123I-FP-CIT SPECT in order to avoid 
management errors and side effects that increase treatment 
costs. Moreover, the cost of SPECT imaging is much less 
compared to other functional imaging techniques such as 
PET. Overall, it is a safe and well tolerated investigation.64
Conclusion
123I-Ioflupane is a powerful and widely used SPECT 
radiotracer for assisting differential diagnosis in PSs where 
the pathology refers to a striatal dopaminergic deficit. A patho-
logical confirmation from postmortem data following SPECT 
imaging with 123I-Ioflupane is sine qua non for estimating the 
accuracy and the prognostic value of this compound. SPECT 
with 123I-Ioflupane can also be used to monitor treatment 
assessing several dopaminergic medications.
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